Insulin recombinant human
Risk of Acute Bronchospasm in Patients with Chronic Lung Disease
- Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA. [see Warnings and Precautions (5.1)].
- AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. [see Contraindications (4)].
- Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients [see Dosage and Administration (2.5), Warnings and Precautions (5.1)].
Patient Counseling Information
Updated January 2018